The advent of PROTACs that degrade the entire protein target rather than simply inhibiting it bring druggable yet apparently non-functional binding sites into play for medicinal chemists to do their work.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Filippakopoulos, P. et al. Nature 468, 1067–1073 (2010).
Smith, S. G. & Zhou, M.-M. ACS Chem. Biol. 11, 598–608 (2016).
Kadoch, C. & Crabtree, G. R. Sci. Adv. 1, e1500447 (2015).
Vangamudi, B. et al. Cancer Res. 75, 3865–3878 (2015).
Papillon, J. P. N. et al. J. Med. Chem. 61, 10155–10172 (2018).
Farnaby, W. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-019-0294-6 (2019).
Toure, M. & Crews, C. M. Angew. Chem. Int. Edn Engl. 55, 1966–1973 (2016).
Zengerle, M., Chan, K. H. & Ciulli, A. ACS Chem. Biol. 10, 1770–1777 (2015).
Dafydd Owen is a shareholder in Pfizer Inc.
Rights and permissions
About this article
Cite this article
Owen, D. Choosing your druggability battle. Nat Chem Biol 15, 652–653 (2019). https://doi.org/10.1038/s41589-019-0305-7